Dual NOX4/NOX1 inhibition by setanaxib halts cholangiocarcinoma progression by impairing cancer associated fibroblast activation.

MLA

Amengual, Josep, et al. “Dual NOX4/NOX1 Inhibition by Setanaxib Halts Cholangiocarcinoma Progression by Impairing Cancer Associated Fibroblast Activation.” Free Radical Biology & Medicine, vol. 218, June 2024, p. 45. EBSCOhost, https://doi.org/10.1016/j.freeradbiomed.2024.04.160.

APA

Amengual, J., Gonzalez-Sanchez, E., Fuste, N. P., Pons, G., Sererols-Viñas, L., Alay, A., Hijazo-Pechero, S., Martín-Mur, B., Esteve-Codina, A., Ferrer, J., Gores, G. J., Ilyas, S. I., Calvisi, D., Aoudjehane, L., Fouassier, L., Coulouarn, C., Affo, S., Fabregat, I., & Vaquero, J. (2024). Dual NOX4/NOX1 inhibition by setanaxib halts cholangiocarcinoma progression by impairing cancer associated fibroblast activation. Free Radical Biology & Medicine, 218, 45. https://doi.org/10.1016/j.freeradbiomed.2024.04.160

Chicago

Amengual, Josep, Ester Gonzalez-Sanchez, Noel P. Fuste, Gabriel Pons, Laura Sererols-Viñas, Ania Alay, Sara Hijazo-Pechero, et al. 2024. “Dual NOX4/NOX1 Inhibition by Setanaxib Halts Cholangiocarcinoma Progression by Impairing Cancer Associated Fibroblast Activation.” Free Radical Biology & Medicine 218 (June): 45. doi:10.1016/j.freeradbiomed.2024.04.160.